Decellularized extracellular matrix (dECM) products are widely established for soft tissue repair, reconstruction and reinforcement. These regenerative biomaterials mimic native tissue ECM with respect to structure and biology and are produced from a range of tissue sources and species. Optimal source tissue processing requires a balance between removal of cellular material and the preservation of structural and biological properties of tissue ECM. Despite the wide-spread clinical use of dECM products there is a lack of comparative information on these products Structurally, some dECM products showed a well-preserved collagen architecture with a broad porosity distribution, while others showed a significantly altered structure compared with native tissue. Decellularization varied across the products. Some materials surveyed (OFMm, PPN, PPC, OFMo, UBM, SISz, ADM, PADM and BADM) were essentially devoid of nuclear bodies (mean count of <5 cells per high powered field (HPF)), whereas others (SISu and SISb) demonstrated an abundance of nuclear bodies (>50 cells per HPF). Pathology assessment of the products demonstrated that OFMm, OFMo and PADM had the highest qualitative assessment score for collagen fiber orientation and arrangement, matrix porosity, decellularization efficiency, and residual vascular channels scoring 10.5±0.8, 12.8±1.0, and 9.7±0.7 out of a maximum total score of 16, respectively This analysis of commercially available dECM products in terms of their structure and cellularity includes 12 different commercial materials The findings highlight the variability of the products in terms of matrix structure and the efficacy of decellularization.
Read full abstract